Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: LaurietCecília Monteiro, William Alvin McElveen, Kristin R. Wildsmith et al.|Neurology|2023Cited by 104